# Impact of Chronic Obstructive Pulmonary Disease on Incidence, Microbiology and Outcome of Ventilator-Associated Lower Respiratory Tract Infections

Anahita Rouze, Pauline Boddaert, Ignacio Martin-Loeches, Pedro Povoa, Alejandro Rodriguez, Nassima Ramdane, Jorge Salluh, Marion Houard, Saad Nseir

► To cite this version:

Anahita Rouze, Pauline Boddaert, Ignacio Martin-Loeches, Pedro Povoa, Alejandro Rodriguez, et al. Impact of Chronic Obstructive Pulmonary Disease on Incidence, Microbiology and Outcome of Ventilator-Associated Lower Respiratory Tract Infections. Microorganisms, 2020, 8 (2), pp.165. 10.3390/microorganisms8020165. [https://doi.org/10.3390/microorganisms8020165](https://doi.org/10.3390/microorganisms8020165)

HAL Id: hal-03325578

https://hal.univ-lille.fr/hal-03325578

Submitted on 25 Aug 2021

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
<figure><img src="image_2.png" /></figure>

Article

# Impact of Chronic Obstructive Pulmonary Disease on Incidence, Microbiology and Outcome of Ventilator-Associated Lower Respiratory Tract Infections

Anahita Rouzé<fnref n="1" />, Pauline Boddaert <fnref n="1" />,<fnref n="2" />, Ignacio Martin-Loeches <fnref n="3" />,<fnref n="4" /> ID, Pedro Povoa <fnref n="5" />, Alejandro Rodriguez <fnref n="6" />, Nassima Ramdane <fnref n="7" />, Jorge Salluh <fnref n="8" />, Marion Houard <fnref n="1" /> and Saad Nseir <fnref n="1" />,<fnref n="2" />,* ID

Received: 3 January 2020; Accepted: 18 January 2020; Published: 23 January 2020

<figure><img src="image_3.png" /></figure>

check for
updates

**Abstract:** Objectives: To determine the impact of chronic obstructive pulmonary disease (COPD) on incidence, microbiology, and outcomes of ventilator-associated lower respiratory tract infections (VA-LRTI). Methods: Planned ancillary analysis of TAVeM study, including 2960 consecutive adult patients who received invasive mechanical ventilation (MV) > 48 h. COPD patients (n = 494) were compared to non-COPD patients (n = 2466). The diagnosis of ventilator-associated tracheobronchitis (VAT) and ventilator-associated pneumonia (VAP) was based on clinical, radiological and quantitative microbiological criteria. Results: No significant difference was found in VAP (12% versus 13%, *p* = 0.931), or VAT incidence (13% versus 10%, *p* = 0.093) between COPD and non-COPD patients. Among patients with VA-LRTI, *Escherichia coli* and *Stenotrophomonas maltophilia* were significantly more frequent in COPD patients as compared with non-COPD patients. However, COPD had no significant impact on multidrug-resistant bacteria incidence. Appropriate antibiotic treatment was not significantly associated with progression from VAT to VAP among COPD patients who developed VAT, unlike non-COPD patients. Among COPD patients, patients who developed VAT or VAP had significantly longer MV duration (17 days (9–30) or 15 (8–27) versus 7 (4–12), *p* < 0.001) and intensive care unit (ICU) length of stay (24 (17–39) or 21 (14–40) versus 12 (8–19), *p* < 0.001) than patients without VA-LRTI. ICU mortality was also higher in COPD patients who developed VAP (44%), but not VAT (38%), as compared to no VA-LRTI (26%, *p* = 0.006). These worse outcomes associated with VA-LRTI were similar among non-COPD patients. Conclusions: COPD had no significant impact on incidence or outcomes of patients who developed VAP or VAT.

**Keywords:** chronic obstructive pulmonary disease; ventilator-associated; lower respiratory tract infections; pneumonia; tracheobronchitis; mechanical ventilation; intensive care

<footnote n="1">¹ Centre Hospitalier Universitaire Lille, Critical Care Center, F-59000 Lille, France; anahita.rouze@chru-lille.fr (A.R.); pauline.boddaert@vhru-lille.fr (P.B.); marion.houard@chru-lille.fr (M.H.)</footnote>

<footnote n="2">² Medicine Faculty, University of Lille, F-59000 Lille, France</footnote>

<footnote n="3">³ Department of Intensive Care Medicine, Multidisciplinary Intensive Care Research Organization (MICRO), St. James's Hospital, St. James Street, Dublin 8, D08 NHY1 Dublin, Ireland; drmartinloeches@gmail.com</footnote>

<footnote n="4">⁴ Hospital Clinic, IDIBAPS, Universidad de Barcelona, Ciberes, 08036 Barcelona, Spain</footnote>

<footnote n="5">5 Nova Medical School, New University of Lisbon, 1099-085 Lisbon, Portugal; pedropovoa@gmail.com</footnote>

<footnote n="6">6 ICU, Hospital Universitari de Tarragona Joan XXIII, 43005 Tarragona, Spain; ahr1161@yahoo.es</footnote>

<footnote n="7">⁷ Centre Hospitalier Universitaire Lille, University of Lille, EA 2694—Santé Publique, Epidémiologie et Qualité des Soins, Département de Biostatistiques, F-59000 Lille, France; nassima.ramdane@chru-lille.fr</footnote>

<footnote n="8">⁸ Institute for Research and Education, D'Or, Rio de Janeiro 22281-100, Brazil; jorgesalluh@gmail.com</footnote>

<footnote>* Correspondence: s-nseir@chru-lille.fr; Tel.: +33-3-20-44-40-84</footnote>
# 1. Introduction

Chronic obstructive pulmonary disease (COPD) is characterized by persistent airflow limitation, associated with an enhanced chronic inflammatory response in the airways and the lung to noxious particles or gases [1]. According to the WHO, over 65 million people have moderate to severe COPD worldwide. With an increasing prevalence, COPD is thought to become the third cause of death in the world by 2030 [2]. In a large Austrian cohort including 194,453 critically ill patients [3], COPD was present in 8.6% of all patients, including one third admitted for acute respiratory failure due to COPD and two thirds with only comorbid COPD. Although use of noninvasive ventilation in acute exacerbations of COPD has substantially reduced the need for intubation, a large proportion of COPD patients still require invasive mechanical ventilation (MV). The largest prospective international cohorts of mechanically ventilated patients reported 10% of critically ill patients receiving MV because of acute exacerbation of COPD in 1998, and still 6% in 2010 [4].

Ventilator-associated lower respiratory tract infections (VA-LRTI), including both ventilator-associated tracheobronchitis (VAT) and ventilator-associated pneumonia (VAP), are the most common healthcare-associated infections among critically ill patients receiving MV. Approximately, one out of four patients intubated for more than 48 h develop VA-LRTI [5]. Intubated COPD patients may be at increased risk for VA-LRTI. Specific risk factors in this population include: (1) prolonged duration of invasive MV, linked with skeletal and diaphragmatic muscle weakness; (2) high incidence of microaspiration, due to gastro-esophageal reflux and altered interaction between breathing and deglutition, resulting in high tracheobronchial bacterial colonization, also favored by defective mucociliary clearance; and (3) altered general host defense mechanisms [6].

Several studies have identified COPD as independently associated to VAP occurrence [7,8], but more recent data suggest that COPD patients may not be at higher risk for VAP [9]. However, VAP is associated with prolonged MV and intensive care unit (ICU) stay, and higher mortality among critically ill patients [5,10], including COPD population [9,11], although mortality attributable to VAP is still a matter for debate [12].

Further, VAT has been proposed as an intermediate stage between tracheobronchial colonization and VAP [13,14]. Several studies have already reported that VAT could progress to VAP, and was associated with longer duration of MV and ICU stay [15–18]. Recently, our group have confirmed that VAT was a separate entity, responsible itself for increased duration of MV and ICU stay in a large cohort of medical and surgical patients [5]. VAT was not associated with increased mortality rates, but transition from VAT to VAP was a risk factor for mortality and appropriate antibiotic treatment decreased both subsequent pneumonia rate and mortality.

However, to our knowledge, no study to date has specifically evaluated VAT among COPD population. One could hypothesize a higher incidence of VAT, as well as worse outcomes, in this particular population. Additionally, as previously mentioned, conflicting epidemiological data exist regarding the impact of COPD on the incidence of VAP. Therefore, we conducted this study to determine the impact of COPD on the incidence, microbiology, and outcomes of patients with VA-LRTI.

# 2. Patients and Methods

## 2.1. *Study Design and Population*

This study is a planned ancillary analysis of TAVeM study [5]. TAVeM is a large prospective multinational observational study conducted in 114 ICUs in Europe (Spain, France, Portugal) and South America (Brazil, Argentina, Ecuador, Bolivia and Colombia), which consecutively included, between September 2013 and July 2014, 2960 patients older than 18 years, who received invasive MV for more than 48 h, and prospectively collected data regarding VA-LRTI, defined as VAT and VAP. Readmitted patients and patients who had been previously tracheostomised were not included. Participating centers either received ethics approval from their institutions or ethics approval was
waived (institutional review board number 2013515). Informed consent was waived because of the observational nature of the study.

## 2.2. Data Collection

Patients were prospectively followed up for VA-LRTI diagnosis and outcome data until death or discharge from hospital [5]. Patient demographic characteristics, severity scores, comorbidities, primary diagnoses, prior antibiotic exposure (during the three months preceding ICU admission) were recorded at baseline for all patients. Further, data about clinical, biological and radiological diagnostic criteria for VA-LRTI, microbiological diagnostic procedures, bacteriological findings, degree of severity on the onset of infection, antibiotic use and clinical outcomes were obtained.

## 2.3. Definitions

### 2.3.1. Chronic Obstructive Pulmonary Disease

Patients were considered as having COPD if exhibiting documented medical history, namely pulmonary function tests before admission, but also compatible clinical and/or radiological criteria, such as smoking exposure, history of acute exacerbations, hyperinflation or emphysema on chest X-ray, expiratory flow limitation during controlled MV [1].

### 2.3.2. Ventilator-Associated Lower Respiratory Tract Infection

The diagnosis of VA-LRTI was based on the presence of at least two of the following criteria [5]: body temperature of more than 38.5 °C or less than 36.5 °C, leucocyte count greater than 12,000 cells per µL or less than 4000 cells per µL, and purulent secretions. Additionally, all episodes of infection needed microbiological confirmation, with the isolation in the endotracheal aspirate of at least 10⁵ colony-forming units (CFU) per mL, or in bronchoalveolar lavage of at least 10⁴ CFU per mL, to be included in the final analysis.

VAT was defined with the above-mentioned criteria with no radiographical signs of new pneumonia. VAP was defined by the presence of new or progressive infiltrates on chest radiograph.

Only first episodes of VAT and VAP were analyzed. VAP was defined as occurring subsequently to VAT if it was diagnosed in the 96 h period after diagnosis of VAT and if the same microorganism caused both infections.

### 2.3.3. Antibiotic Treatment and Microbiological Data

Antibiotic was considered appropriate if it matched the in vitro susceptibility of the pathogen causing VA-LRTI [19]. Microbiological identification and susceptibility tests were performed using standard methods. Multidrug resistant (MDR) isolates were defined as acquired non-susceptibility to at least one agent in three or more antimicrobial categories [20].

## 2.4. Outcomes

The primary aim of our study was to determine the impact of COPD on the incidence of VA-LRTI, including VAT and VAP.

Our secondary objectives were to determine the impact of COPD on the microbiology and outcomes (duration of MV, length of stay in the ICU, in the hospital, and ICU mortality) of VA-LRTI. We also studied diagnostic data, antibiotic treatment data, and the effect of antibiotic treatment on progression from VAT to VAP in COPD as compared to non-COPD patients.

## 2.5. Statistical Analysis

Categorical variables were expressed as numbers (percentages) and compared using Chi-square test or Fisher's exact test, as appropriate. Normality of distribution of continuous variables was checked graphically and by using the Shapiro-Wilk test. As all continuous variables were skewed,
they were presented as medians (interquartile ranges), and compared using Mann-Whitney *U* test or Kruskal-Wallis test. Adjusted analyses on age and gender were performed using non-parametric analysis of covariance for continuous variables and logistic regression for categorical variables. Univariate and multivariate analyses to determine factors associated with ICU mortality in patients with ventilator associated lower respiratory tract infection were also performed. All variables with a *p*-value < 0.1 in univariate analysis were included in a logistic regression model using a stepwise backward elimination. All statistical tests were two-tailed, and *p* values < 0.05 were considered statistically significant. The Statistics Department of Lille University Hospital performed all data analyses using SAS software package, release 9.4 (SAS Institute, Cary, NC, USA).

# 3. Results

## 3.1. *Baseline Patient Characteristics*

Among the 2960 included patients, 494 (17%) had COPD. Age, percentage of men, percentage of patients with chronic diseases such as diabetes mellitus, chronic respiratory failure, chronic kidney disease, and alcohol abuse, were significantly higher in COPD patients compared with non-COPD patients. COPD patients were significantly more frequently admitted to the ICU for medical reasons, with a higher percentage of pneumonia as the main cause of admission, compared with non-COPD patients (Table 1).

<table><caption>**Table 1.** Patient characteristics at intensive care unit (ICU) admission in chronic obstructive pulmonary disease (COPD) and non-COPD patients.</caption><thead><tr><th></th><th>COPD<br>n = 494</th><th>No COPD<br>n = 2466</th><th>p</th></tr></thead><tbody><tr><td>Age, years</td><td>68 (60–76)</td><td>63 (49–74)</td><td>&lt;0.001</td></tr><tr><td>Male gender</td><td>355 (72)</td><td>1494 (61)</td><td>&lt;0.001</td></tr><tr><td>Severity scores</td><td></td><td></td><td></td></tr><tr><td>SAPS II</td><td>50 (39–62)</td><td>50 (37–63)</td><td>0.27</td></tr><tr><td>SOFA score</td><td>8 (5–10)</td><td>8 (5–11)</td><td>0.29</td></tr><tr><td>Comorbidities</td><td></td><td></td><td></td></tr><tr><td>Diabetes mellitus</td><td>126 (26)</td><td>442 (18)</td><td>&lt;0.001</td></tr><tr><td>Chronic respiratory failure</td><td>187 (38)</td><td>99 (4)</td><td>&lt;0.001</td></tr><tr><td>Chronic heart failure</td><td>36 (7)</td><td>176 (7)</td><td>0.91</td></tr><tr><td>Chronic kidney disease</td><td>76 (15)</td><td>217 (9)</td><td>&lt;0.001</td></tr><tr><td>Cirrhosis</td><td>25 (5)</td><td>152 (6)</td><td>0.35</td></tr><tr><td>Immunosuppression</td><td>113 (23)</td><td>549 (22)</td><td>0.77</td></tr><tr><td>Alcohol abuse</td><td>84 (17)</td><td>274 (11)</td><td>&lt;0.001</td></tr><tr><td>Intravenous drug abuse</td><td>10 (2)</td><td>43 (2)</td><td>0.67</td></tr><tr><td>Category of admission</td><td></td><td></td><td>&lt;0.001</td></tr><tr><td>Medical</td><td>392 (79)</td><td>1496 (61)</td><td></td></tr><tr><td>Surgical</td><td>68 (14)</td><td>476 (19)</td><td></td></tr><tr><td>Trauma</td><td>34 (7)</td><td>494 (20)</td><td></td></tr><tr><td>Main causes for ICU admission</td><td></td><td></td><td></td></tr><tr><td>Shock</td><td>33 (7)</td><td>238 (10)</td><td>0.037</td></tr><tr><td>Sepsis</td><td>54 (11)</td><td>284 (12)</td><td>0.71</td></tr><tr><td>Acute respiratory distress syndrome</td><td>23 (5)</td><td>124 (5)</td><td>0.73</td></tr><tr><td>Pneumonia</td><td>110 (22)</td><td>308 (12)</td><td>&lt;0.001</td></tr><tr><td>Aspiration</td><td>5 (1)</td><td>44 (2)</td><td>0.22</td></tr><tr><td>Congestive heart failure</td><td>20 (4)</td><td>76 (3)</td><td>0.27</td></tr><tr><td>Myocardial infarction</td><td>12 (2)</td><td>57 (2)</td><td>0.87</td></tr><tr><td>Arrhythmia</td><td>6 (1)</td><td>28 (1)</td><td>0.88</td></tr><tr><td>Coma</td><td>26 (5)</td><td>248 (10)</td><td>&lt;0.001</td></tr><tr><td>Stroke</td><td>6 (1)</td><td>115 (5)</td><td>&lt;0.001</td></tr><tr><td>Seizure</td><td>5 (1)</td><td>66 (3)</td><td>0.027</td></tr><tr><td>Brain aneurysm</td><td>5 (1)</td><td>37 (2)</td><td>0.40</td></tr><tr><td>Traumatic brain injury</td><td>6 (1)</td><td>153 (6)</td><td>&lt;0.001</td></tr><tr><td>Acute renal failure</td><td>9 (2)</td><td>36 (1)</td><td>0.55</td></tr></tbody></table>

Data are presented as number (%) or median (interquartile range). COPD, chronic obstructive pulmonary disease; ICU, intensive care unit; SAPS, simplified acute physiology score; SOFA, sequential organ failure assessment. Some patients had more than one cause for ICU admission.
Prior antibiotic use was significantly more frequent in COPD patients compared with non-COPD patients who developed VA-LRTI (95 of 121 (78.5%) versus 347 of 530 (65.5%), *p* = 0.0056).

## 3.2. Incidence of Ventilator-Associated Lower Respiratory Tract Infections

No significant difference was found in the incidence of VAP (12% versus 13%, *p* = 0.931), or VAT (13% versus 10%, *p* = 0.093) between COPD and non-COPD patients (Figure 1). No significant difference was found in the rate of transition from VAT to VAP (17% versus 11% of VAT episodes, *p* = 0.172) between COPD and non-COPD patients.

<figure><img src="image_4.png" /><figcaption>**Figure 1.** Study flowchart. Data are presented as number of patients. Only first episodes of VA-LRTI were taken into account. COPD, Chronic Obstructive Pulmonary Disease; VA-LRTI, ventilator-associated lower respiratory tract infection; VAP, ventilator-associated pneumonia; VAT, ventilator-associated tracheobronchitis.</figcaption></figure>

## 3.3. Characteristics of Ventilator-Associated Lower Respiratory Tract Infections

### 3.3.1. Diagnostic Data

On the day of VA-LRTI diagnosis, SOFA score and PCT were not significantly different in COPD patients who developed VAP as compared to patients who developed VAT, unlike in non-COPD patients (Table 2). However, clinical pulmonary infection score (CPIS) was significantly higher in VAP than in VAT patients, both in COPD and non-COPD population.

In both COPD and non-COPD patients, bronchoalveolar lavage was significantly more frequently used to diagnose VAP than VAT. Nevertheless, significantly higher proportion of COPD patients had invasive microbiological diagnostic tests, i.e., bronchoscopy or bronchoalveolar lavage, than did non-COPD patients, in both VAT and VAP groups (Table 2).
<table><caption>**Table 2.** Biological criteria and microbiological diagnostic procedures used in ventilator-associated lower respiratory tract infection diagnosis in COPD and non-COPD patients.</caption><thead><tr><th rowspan="2"></th><th colspan="3">COPD<br>n = 125</th><th colspan="3">No COPD<br>N = 564</th></tr><tr><th>VAT<br>n = 64</th><th>VAP<br>n = 61</th><th>p</th><th>VAT<br>n = 256</th><th>VAP<br>n = 308</th><th>p</th></tr></thead><tbody><tr><td>CRP</td><td>69 (9–201)</td><td>129 (17–230)</td><td>0.374</td><td>126 (51–211)</td><td>120 (30–239)</td><td>0.78</td></tr><tr><td>PCT</td><td>0.1 (0.0–1.7)</td><td>0.8 (0.0–3.8)</td><td>0.219</td><td>0.1 (0.0–1.0)</td><td>0.4 (0.0–5.0)</td><td>&lt;0.001</td></tr><tr><td>CPIS</td><td>5 (3–6)</td><td>6 (5–8)</td><td>&lt;0.001</td><td>4 (3–6)</td><td>7 (5–8)</td><td>&lt;0.001</td></tr><tr><td>Endotracheal aspirate</td><td>52 (81)</td><td>41 (67)</td><td>0.072</td><td>226 (88)</td><td>212 (69)</td><td>&lt;0.001</td></tr><tr><td>Bronchoscopy</td><td>7 (11) *</td><td>15 (25) *</td><td>0.045</td><td>10 (4)</td><td>41 (13)</td><td>&lt;0.001</td></tr><tr><td>Bronchoalveolar lavage</td><td>6 (9) **</td><td>15 (25) **</td><td>0.023</td><td>6 (2)</td><td>44 (14)</td><td>&lt;0.001</td></tr><tr><td>Mini bronchoalveolar lavage</td><td>5 (8)</td><td>4 (7)</td><td>0.786</td><td>11 (4)</td><td>41 (13)</td><td>&lt;0.001</td></tr><tr><td>Blind protected specimen brush</td><td>8 (13)</td><td>12 (20)</td><td>0.274</td><td>24 (9)</td><td>39 (13)</td><td>0.22</td></tr></tbody></table>

Data are presented as number (%) or median (interquartile range). COPD, chronic obstructive pulmonary disease; VAP, ventilator-associated pneumonia; VAT, ventilator-associated tracheobronchitis; CRP, C-reactive protein; PCT, procalcitonin; CPIS, clinical pulmonary infection score. *p* values are for comparison between VAT and VAP groups. *p* = 0.008 and **p** = 0.005 versus patients with no COPD.

### 3.3.2. Microbiological Data

Among patients with VA-LRTI, *Escherichia coli* and *Stenotrophomonas maltophilia* were significantly more frequent in COPD patients as compared with non-COPD patients (Table 3). The rate of MDR bacteria was not significantly different between COPD and non-COPD patients.

<table><caption>**Table 3.** Microbiological findings in COPD and non-COPD patients with ventilator-associated lower respiratory tract infections.</caption><thead><tr><th></th><th>COPD<br>n = 125</th><th>No COPD<br>n = 564</th><th>p</th></tr></thead><tbody><tr><td>Polymicrobial</td><td>33 (26)</td><td>132 (23)</td><td>0.48</td></tr><tr><td>Multidrug-resistant isolates</td><td>75 (60)</td><td>346 (62)</td><td>0.71</td></tr><tr><td>Gram-negative bacilli</td><td></td><td></td><td></td></tr><tr><td>Pseudomonas aeruginosa</td><td>32 (26)</td><td>136 (24)</td><td>0.73</td></tr><tr><td>Escherichia coli</td><td>23 (18)</td><td>54 (10)</td><td>0.005</td></tr><tr><td>Klebsiella pneumoniae</td><td>15 (12)</td><td>86 (15)</td><td>0.35</td></tr><tr><td>Enterobacter spp.</td><td>15 (12)</td><td>66 (12)</td><td>0.93</td></tr><tr><td>Stenotrophomonas maltophilia</td><td>11 (9)</td><td>20 (4)</td><td>0.010</td></tr><tr><td>Haemophilus influenzae</td><td>7 (6)</td><td>50 (9)</td><td>0.23</td></tr><tr><td>Proteus mirabilis</td><td>7 (6)</td><td>22 (4)</td><td>0.39</td></tr><tr><td>Serratia marcescens</td><td>5 (4)</td><td>23 (4)</td><td>0.97</td></tr><tr><td>Acinetobacter baumannii</td><td>4 (3)</td><td>37 (7)</td><td>0.15</td></tr><tr><td>Citrobacter freundii</td><td>3 (2)</td><td>10 (2)</td><td>0.71</td></tr><tr><td>Gram-positive cocci</td><td></td><td></td><td></td></tr><tr><td>MSSA</td><td>21 (17)</td><td>125 (22)</td><td>0.18</td></tr><tr><td>MRSA</td><td>4 (3)</td><td>12 (2)</td><td>0.51</td></tr><tr><td>Streptococcus pneumoniae</td><td>8 (6)</td><td>32 (6)</td><td>0.75</td></tr></tbody></table>

Data are presented as number (%). COPD, chronic obstructive pulmonary disease; MRSA, meticillin-resistant *Staphylococcus aureus*; MSSA, meticillin-sensitive *Staphylococcus aureus*.

### 3.3.3. Impact of Antibiotic Treatment on Transition from VAT to VAP

In COPD patients, no significant difference was found in rate of antibiotic treatment, appropriate antibiotic treatment, or duration of antibiotic treatment between patients with transition from VAT to VAP, as compared with those with no transition from VAT to VAP (Table 4).
<table><caption>**Table 4.** Antibiotic use in COPD and non-COPD patients with ventilator-associated tracheobronchitis.</caption><thead><tr><th rowspan="2"></th><th colspan="2">COPD<br>n = 64</th><th colspan="2">No COPD<br>n = 256</th></tr><tr><th>VAT to VAP<br>Progression<br>n = 11</th><th>No VAT to VAP<br>Progression<br>n = 53</th><th>p</th><th>VAT to VAP<br>Progression<br>n = 28</th><th>No VAT to VAP<br>Progression<br>n = 228</th><th>p</th></tr></thead><tbody><tr><td>Antibiotic treatment</td><td>10 (91)</td><td>50 (94)</td><td>0.539</td><td>21 (75)</td><td>213 (93)</td><td>0.005</td></tr><tr><td>Appropriate antibiotic<br>treatment</td><td>6 (55)</td><td>42 (79)</td><td>0.124</td><td>13 (46)</td><td>189 (83)</td><td>&lt;0.001</td></tr><tr><td>Length of antibiotic<br>treatment, days</td><td>7 (3–8)</td><td>7 (4–10)</td><td>0.591</td><td>6 (4–10)</td><td>7 (4–10)</td><td>0.99</td></tr></tbody></table>

Data are presented as number (%) or median (interquartile range). COPD, chronic obstructive pulmonary disease; VAP, ventilator-associated pneumonia; VAT, ventilator-associated tracheobronchitis. *p* values are for comparison between VAT to VAP and no VAT to VAP groups.

### 3.4. Outcomes of Ventilator-Associated Lower Respiratory Tract Infections

In COPD patients, MV, ICU and hospital length of stay were significantly different between patients with VAT, VAP, or no VA-LRTI, as in non-COPD patients. ICU mortality was also significantly different in these three groups of patients in both COPD and non-COPD populations: VAP was associated with a higher mortality compared to VAT and no-VALRTI among non-COPD patients, and only compared to no-VALRTI among COPD patients. COPD had no significant impact on duration of MV, length of ICU or hospital stay, or mortality in patients with VA-LRTI. In patients without VA-LRTI, COPD patients exhibited significantly lower ICU mortality, as compared to non-COPD patients (Table 5). Factors associated with ICU mortality in patients with VA-LRTI in univariate and multivariate analyses are shown in Table S1 (supplementary material).

<table><caption>**Table 5.** Clinical outcomes of study patients.</caption><thead><tr><th rowspan="2"></th><th colspan="4">COPD<br>n = 494</th><th colspan="4">No COPD<br>n = 2466</th></tr><tr><th>VAT<br>n = 64</th><th>VAP<br>n = 61</th><th>No<br>VA-LRTI<br>n = 369</th><th>p</th><th>VAT<br>n = 256</th><th>VAP<br>n = 308</th><th>No<br>VA-LRTI<br>n = 1902</th><th>p</th></tr></thead><tbody><tr><td>MV duration, days</td><td>17(9–30)</td><td>15(8–27)</td><td>7(4–12)</td><td>&lt;0.001</td><td>13(8–21)</td><td>15(8–26)</td><td>7(4–13)</td><td>&lt;0.001</td></tr><tr><td>ICU length of stay, days</td><td>24(17–39)</td><td>21(14–40)</td><td>12(8–19)</td><td>&lt;0.001</td><td>20(14–31)</td><td>21(13–33)</td><td>12(8–19)</td><td>&lt;0.001</td></tr><tr><td>Hospital length of stay, days</td><td>42(22–59)</td><td>30(18–56)</td><td>23(14–38)</td><td>&lt;0.001</td><td>36(21–54)</td><td>31(20–54)</td><td>23(14–41)</td><td>&lt;0.001</td></tr><tr><td>ICU mortality</td><td>24 (38) <sup>$</sup></td><td>27 (44)</td><td>95 (26) <sup>*</sup></td><td>0.006</td><td>68 (27) <sup>£</sup></td><td>116 (38)</td><td>565 (30)</td><td>&lt;0.001</td></tr></tbody></table>

Data are presented as number (%) or median (interquartile range). *p* values are adjusted on age and gender using non-parametric analysis of covariance for continuous variables and logistic regression for categorical variables. COPD, chronic obstructive pulmonary disease; ICU, intensive care unit; MV, mechanical ventilation; VA-LRTI, ventilator-associated lower respiratory tract infection; VAP, ventilator-associated pneumonia; VAT, ventilator-associated tracheobronchitis. *p* values are for comparisons between the three groups. <sup>$</sup> *p* > 0.999 versus VAP, *p* = 0.150 versus no VA-LRTI, <sup>£</sup> *p* = 0.002 versus VAP, *p* > 0.999 versus no VA-LRTI, <sup>*</sup> *p* = 0.012 versus non-COPD patients with no VA-LRTI, *p* > 0.05 for all other comparisons between COPD and non-COPD patients.

## 4. Discussion

The main results of our study are as follows: (1) the incidence of VAP and VAT was not significantly different between COPD and non-COPD patients. (2) Among patients with VA-LRTI, *E. coli* and *S. maltophilia* were significantly more frequent in COPD patients as compared with non-COPD patients. The rate of MDR bacteria was not significantly different between the two groups. (3) Among COPD patients, those with VAT or VAP had significantly longer MV duration, ICU and hospital length of stay, as compared to patients without VA-LRTI. ICU mortality was also higher among COPD patients who developed VAP as compared to patients without VA-LRTI. These worse outcomes associated with VA-LRTI were similarly found among non-COPD patients. (4) Appropriate antibiotic treatment was
not significantly associated with progression from VAT to VAP among COPD patients who developed VAT, unlike non-COPD patients.

To the best of our knowledge, our study is the first to evaluate the relationship between COPD and VA-LRTI, specifically including VAT. It benefits from several strengths of TAVeM study, which constitutes the largest prospective multicenter international cohort of VA-LRTI, with strict diagnostic criteria, obtaining data from consecutive patients, and generating robust and reproducible results [5].

Among intubated COPD patients, VAP incidence widely ranges, from 6 to 34% [7–9,11], possibly because of different VAP diagnostic criteria used in these studies. The relatively low rate of VAP among COPD patients, together with the lack of significant difference with non-COPD patients, may be due to the significantly higher previous exposure to antibiotics in COPD patients. Previous studies reported that antibiotic treatment could be protective against VAP [21]. However, antibiotic treatment is well-known risk factor for late-onset ICU-acquired infections, and MDR bacteria emergence [22]. Our results contradict several earlier studies that identified COPD as an independent risk factor for VAP [7,8], but are in line with data from a recent retrospective analysis of a large prospective observational study conducted in 27 European ICUs and including 2082 intubated patients, which reported a similar 20% incidence of VAP among COPD and non COPD patients [9].

In addition, differentiating VAT and VAP episodes in COPD patients can be challenging, as the interpretation of chest X-ray to identify new or progressive infiltrates, may be particularly tricky in this population with baseline abnormal radiographs. This might have resulted in a misclassification of VA-LRTI episodes. Using CT scan or lung ultrasound to diagnose pneumonia may be a future option to effectively differentiate VAT and VAP in COPD patients, as some authors have recently proposed for community-acquired pneumonia [23,24]. However, baseline CT would be needed, and indications should be carefully evaluated, as transport of critically ill patients to the radiology department was repeatedly reported to be associated with adverse events [25].

Little but consistent data are available on the microbiology of VAP in COPD patients [9,11,26]. Gram-negative bacilli are the most frequently isolated microorganisms in this population, with a high proportion of *Pseudomonas aeruginosa*, around one third of responsible bacteria, followed by *Acinetobacter baumannii* and *Staphylococcus aureus*. Koulenti et al. recently reported a higher prevalence of *P. aeruginosa* in VAP among COPD patients, as compared to non COPD patients (29 versus 19%, *p* = 0.04) [9]. The high proportion of MDR bacteria in COPD patients with VAP could be explained by the frequent antimicrobial treatments and hospitalizations in this population [27]. Our results showed significantly higher rates of *S. maltophilia* and *E. coli* in COPD patients as compared with non-COPD patients. However, no significant difference was found in MDR bacteria, or *P. aeruginosa* rates between COPD, and non-COPD patients. COPD has been previously reported as an independent risk factor for *S. maltophilia* ICU-acquired infections [28]. The absence of significant difference in MDR bacteria rate between COPD and non-COPD patients could be explained by high rates of MDR bacteria in both COPD and non-COPD population, and different local epidemiology.

Our results suggest that COPD itself is not associated with negative impact on outcome of VAP or VAT patients, as same worse outcomes were observed among COPD and non-COPD patients in our cohort, as compared to patients without VA-LRTI. Our results are in line with the recent large European cohort of intubated critically ill patients, including 397 COPD patients, which reported a 17% significant increase of ICU mortality in COPD patients who developed VAP, as compared to COPD patients without VAP, and identified the occurrence of VAP as an independent predictor of mortality among COPD patients (odds ratio 2.28, 95% confidence interval 1.35–3.87) [9]. However, a prospective observational study including 215 patients with VAP, observed a significantly higher ICU mortality in COPD patients compared with non COPD patients (60 versus 43%, *p* = 0.027) and identified COPD as an independent risk factor for ICU mortality in multivariate analysis (odds ratio 2.58, 95% confidence interval 1.34–5) [26]. At least two potential explanations could be given for the absence of significant impact of COPD on outcomes of VAP patients in our study. First, our study
might have been underpowered to detect such an effect. Second, the definition used for COPD was
probably not specific, as lung function testing results were not available.

Besides, COPD has been considered a risk factor of death in ICU. A quite recent prospective study including 235 ventilated patients without evidence of respiratory infection showed that COPD was independently associated with mortality (hazard ratio 2.1 [1.10–3.94]) [29]. Interestingly, our data suggest the opposite in the subgroup of patients without VA-LRTI, in which COPD was associated with significantly lower ICU mortality.

The rate of progression from VAT to VAP was similar in COPD and non-COPD patients in our study, suggesting that COPD is not a risk factor for progression from VAT to VAP. Antibiotic treatment, either appropriate or not, did not significantly reduce the progression from VAT to VAP among COPD patients. This result could be explained by the small number of COPD patients with transition from VAT to VAP.

Our study has several limitations. First, this was a planned analysis of a prospective database not initially designed to evaluate the relationship between COPD and VA-LRTI. The presence of COPD was recorded by the attending physician, based on pulmonary function tests before ICU admission, or compatible clinical and/or radiological criteria. Furthermore, data regarding the severity of COPD, such as GOLD stages, long term oxygen therapy, noninvasive ventilation at home or previous corticosteroid use were not recorded, and results might have been different if specific severity subgroups have been analyzed.

**5. Conclusions**

Our study suggests that COPD does not impact the incidence or the outcome of VA-LRTI. However, higher rates of *S. maltophilia*, and *E. coli* were found in COPD patients with VA-LRTI, as compared with non COPD patients.

**Supplementary Materials:** The following are available online at http://www.mdpi.com/2076-2607/8/2/165/s1.

**Author Contributions:** A.R. (Anahita Rouzé), P.B. and S.N. designed the study. A.R. (Anahita Rouzé), P.B., I.M.-L., P.P., A.R. (Alejandro Rodriguez), N.R., J.S., M.H. and S.N. collected the data. A.R., P.B., and S.N. wrote the manuscript. All authors made substantial contribution. All authors read and approved the final version of the manuscript.

**Funding:** This research received no external funding.

**The TAVeM Study Group Included the Following Contributors:** Ignacio Martín-Loeches, Alejandro Rodriguez, Daniel Curcio, Rubén Oscar Fernández, Jorge Arroyo, Maria Gabriela, Rodriguez Alvarez, Alex Tamayo Reyes, Christian Dellera, Francisco Molina, Daniel Molano Franco, Edwin Giovanny Chapeta Parada, Estuardo Salgado Yepez, Fernando Paredes Oña, Diego Morocho Tutillo, Diego Barahona, Francisco Alvarez Lerma, Ana Abella Álvarez, José Manuel Allegue Gallego, Francisco José Fuentes Morillas, Antonio Luis Ruiz Aguilar, María Lourdes Cordero Lorenzana, Rafael Sanchez Iniesta, Jordi Almirall, Antonio Albaya, Sergio Ruiz Santana, Carmen Fernandez, Miguel Angel Blasco Naval Potro, Pablo Vidal Cortes, Belen Jimenez, Rafael Sierra, Maria Del Valle Ortiz, Nieves Cruza, Pedro Maria Olaechea, Ana Carolina Caballero Zirena, Pilar Posada Gonzalez, Teresa Recio Gomez, Lorenzo Socías Crespi, Paula Ramírez Galleymore, Ricard Jordà Marcos, César Palazón, Bernardo Gil Rueda, Juan Carlos Ballesteros, María Pilar Gracia Arnilla, Antonia Socías, Joaquin Amador, Esperanza Molero Silvero, Laura Macaya Redín, Mónica Zamora Elson, Luis Cabré Pericas, Joaquín Álvarez Rodríguez, Mercedes Nieto, Antoni Torres, Elena Molinos, Ana Josefina, Nuno Catorze, Pedro Póvoa, Carlos Candeias, Luis Coelho, Paulo André, José Andrade Gomes, Elisa Vedes, Antero Fernandes, Miguel Ángel García, Catalina Sanchez Ramírez, Milagros Calizaya, Ángel Estella, Adrià Albis, Gerardo Aguilar, Eva Torrents, Marta Gurpegui Puente, Angel Gabriel Sanchez, Thiago Lisboa, Pedro Azambuja, Marcos Freitas Knibel, Otavio Ranzani, Laura Darriba W. Camargo, Antonio Paulo Nassar Junior, Cesar Biselli Ferreira, Suzana Lobo, Ligia Rabello, Marcelo Park, Alexandre Guilherme Ribeiro de Carvalho, Maurício Valencia, Alejandro Gonzalez Castro, Adoración Alcalá López, José María Castillo Caballero, Saad Nseir, Karim Jaffal, Erika Parmentier-Decrucq, Sébastien Préau, Chloé Rousselin, Caroline Blazejewski, Juliette Masse, Laurent Robriquet, Léa Satre-Buisson, Jean-Paul Mira, Nathalie Martin, Raphael Lepecq, Hervé Mentec, Christophe Girault, Antoine Marchalot, Jonathan Messika, Jean-Damien Ricard, Philippe Seguin, Bruno Mégarbane, Sandrine Valade, Elie Azoulay, Nicolas Boussekey, Olivier Leroy, Jean Reignier, Marc Clavel, Nicolas Pichon, Thomas Baudry, Laurent Argaud, Pascal Beuret, Ali Ait-Hssain, Martine Nyunga, Isabelle Alves, Florent Dewavrin, Guillaume Brunin, Stéphane Mérat, Pierre Pasquier, Frédéric Brun, Aurore Palud, Benoît Voisin, Romaric Grenot, Nicolas Van Grunderbeeck, Didier Thévenin, Benoît Misset, François Philippart, Jean-Pierre Frat, Rémi Coudroy, Philippe Cabaret, Marie Ledein, Fethi Zoheir Hadj Slimane, Romain Miguel-Montanes, Nicolas Weiss, Francis Bolgert, Bernard Just.
**Ethics Approval and Consent to Participate:** Participating centers either received ethics approval from their institutions or ethics approval was waived (institutional review board number 2013515). Informed consent was waived because of the observational nature of the study.

**Conflicts of Interest:** S.N.: MSD, Pfizer, Biomérieux, Gilead (lecture and advisory board). A.R.: MaatPharma (advisory board). Appendix A. Other authors declare that they have no competing interests.

**Abbreviations**

COPD chronic obstructive pulmonary disease

VA-LRTI ventilator-associated lower respiratory tract infection

MV mechanical ventilation

VAT ventilator-associated tracheobronchitis

VAP ventilator-associated pneumonia

ICU intensive care unit

CFU colony-forming units

**References**

1. Vestbo, J.; Hurd, S.S.; Agustí, A.G.; Jones, P.W.; Vogelmeier, C.; Anzueto, A.; Barnes, P.J.; Fabbri, L.M.; Martinez, F.J.; Nishimura, M.; et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: GOLD Executive Summary. *Am. J. Respir. Crit. Care Med.* **2013**, *187*, 347–365. [CrossRef]

2. World Health Organization Statistics 2008. Available online: https://www-who-int.gate2.inist.fr/gho/publications/world_health_statistics/EN_WHS08_Full.pdf?ua=1 (accessed on 13 August 2019).

3. Funk, G.C.; Bauer, P.; Burghuber, O.C.; Fazekas, A.; Hartl, S.; Hochrieser, H.; Schmutz, R.; Metnitz, P. Prevalence and prognosis of COPD in critically ill patients between 1998 and 2008. *Eur. Respir. J.* **2013**, *41*, 792–799. [CrossRef] [PubMed]

4. Esteban, A.; Frutos-Vivar, F.; Muriel, A.; Ferguson, N.D.; Peñuelas, O.; Abraira, V.; Raymondos, K.; Rios, F.; Nin, N.; Apezteguía, C.; et al. Evolution of mortality over time in patients receiving mechanical ventilation. *Am. J. Respir. Crit. Care Med.* **2013**, *188*, 220–230. [CrossRef] [PubMed]

5. Martin-Loeches, I.; Povoa, P.; Rodríguez, A.; Curcio, D.; Suarez, D.; Mira, J.P.; Cordero, M.L.; Lepecq, R.; Girault, C.; Candeias, C.; et al. Incidence and prognosis of ventilator-associated tracheobronchitis (TAVeM): A multicentre, prospective, observational study. *Lancet Respir. Med.* **2015**, *3*, 859–868. [CrossRef]

6. Rouzé, A.; Cottereau, A.; Nseir, S. Chronic obstructive pulmonary disease and the risk for ventilator-associated pneumonia. *Curr. Opin. Crit. Care* **2014**, *20*, 525–531. [CrossRef] [PubMed]

7. Torres, A.; Aznar, R.; Gatell, J.M.; Jiménez, P.; González, J.; Ferrer, A.; Celis, R.; Rodriguez-Roisin, R. Incidence, Risk, and Prognosis Factors of Nosocomial Pneumonia in Mechanically Ventilated Patients. *Am. Rev. Respir. Dis.* **1990**, *142*, 523–528. [CrossRef]

8. Tejerina, E.; Frutos-Vivar, F.; Restrepo, M.I.; Anzueto, A.; Abroug, F.; Palizas, F.; González, M.; D'Empaire, G.; Apezteguía, C.; Esteban, A.; et al. Internacional Mechanical Ventilation Study Group. Incidence, risk factors, and outcome of ventilator-associated pneumonia. *J. Crit. Care* **2006**, *21*, 56–65. [CrossRef]

9. Koulenti, D.; Blot, S.; Dulhunty, J.M.; Papazian, L.; Martin-Loeches, I.; Dimopoulos, G.; Brun-Buisson, C.; Nauwynck, M.; Putensen, C.; Sole-Violan, J.; et al. COPD patients with ventilator-associated pneumonia: Implications for management. *Eur. J. Clin. Microbiol. Infect. Dis.* **2015**, *34*, 2403–2411. [CrossRef]

10. Melsen, W.G.; Rovers, M.M.; Groenwold, R.H.; Bergmans, D.C.; Camus, C.; Bauer, T.T.; Hanisch, E.W.; Klarin, B.; Koeman, M.; Krueger, W.A.; et al. Attributable mortality of ventilator-associated pneumonia: A meta-analysis of individual patient data from randomised prevention studies. *Lancet Infect. Dis.* **2013**, *13*, 665–671. [CrossRef]

11. Nseir, S.; Di Pompeo, C.; Soubrier, S.; Cavestri, B.; Jozefowicz, E.; Saulnier, F.; Durocher, A. Impact of ventilator-associated pneumonia on outcome in patients with COPD. *Chest* **2005**, *128*, 1650–1656. [CrossRef]

12. Bekaert, M.; Timsit, J.F.; Vansteelandt, S.; Depuydt, P.; Vésin, A.; Garrouste-Orgeas, M.; Decruyenaere, J.; Clec'h, C.; Azoulay, E.; Benoit, D. Attributable mortality of ventilator-associated pneumonia: A reappraisal using causal analysis. *Am. J. Respir. Crit. Care Med.* **2011**, *184*, 1133–1139. [CrossRef]
13. Rodríguez, A.; Póvoa, P.; Nseir, S.; Salluh, J.; Curcio, D.; Martín-Loeches, I. Incidence and diagnosis of ventilator-associated tracheobronchitis in the intensive care unit: An international online survey. *Crit. Care* **2014**, *18*, R32. [CrossRef] [PubMed]

14. Nseir, S.; Povoa, P.; Salluh, J.; Rodriguez, A.; Martin-Loeches, I. Is there a continuum between ventilator-associated tracheobronchitis and ventilator-associated pneumonia? *Intensive Care Med.* **2016**, *42*, 1190–1192. [CrossRef] [PubMed]

15. Dallas, J.; Skrupky, L.; Abebe, N.; Boyle, W.A., III; Kollef, M.H. Ventilator-associated tracheobronchitis in a mixed surgical and medical ICU population. *Chest* **2011**, *139*, 513–518. [CrossRef] [PubMed]

16. Craven, D.E.; Lei, Y.; Ruthazer, R.; Sarwar, A.; Hudcova, J. Incidence and outcomes of ventilator-associated tracheobronchitis and pneumonia. *Am. J. Med.* **2013**, *126*, 542–549. [CrossRef] [PubMed]

17. Nseir, S.; Di Pompeo, C.; Pronnier, P.; Beague, S.; Onimus, T.; Saulnier, F.; Grandbastien, B.; Mathieu, D.; Delvallez-Roussel, M.; Durocher, A. Nosocomial tracheobronchitis in mechanically ventilated patients: Incidence, aetiology and outcome. *Eur. Respir. J.* **2002**, *20*, 1483–1489. [CrossRef]

18. Karvouniaris, M.; Makris, D.; Manoulakas, E.; Zygoulis, P.; Mantzarlis, K.; Triantaris, A.; Chatzi, M.; Zakynthinos, E. Ventilator-associated tracheobronchitis increases the length of intensive care unit stay. *Infect. Control Hosp. Epidemiol.* **2013**, *34*, 800–808. [CrossRef]

19. Paul, M.; Shani, V.; Muchtar, E.; Kariv, G.; Robenshtok, E.; Leibovici, L. Systematic Review and Meta-Analysis of the Efficacy of Appropriate Empiric Antibiotic Therapy for Sepsis. *Antimicrob. Agents Chemother.* **2010**, *54*, 4851–4863. [CrossRef]

20. Magiorakos, A.P.; Srinivasan, A.; Carey, R.B.; Carmeli, Y.; Falagas, M.E.; Giske, C.G.; Harbarth, S.; Hindler, J.F.; Kahlmeter, G.; Olsson-Liljequist, B.; et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. *Clin. Microbiol. Infect.* **2012**, *18*, 268–281. [CrossRef]

21. Bouza, E.; Granda, M.J.P.; Hortal, J.; Barrio, J.M.; Cercenado, E.; Muñoz, P. Pre-emptive broad-spectrum treatment for ventilator-associated pneumonia in high-risk patients. *Intensive Care Med.* **2013**, *39*, 1547–1555. [CrossRef]

22. Nair, G.B.; Niederman, M.S. Ventilator-associated pneumonia: Present understanding and ongoing debates. *Intensive Care Med.* **2014**, *41*, 34–48. [CrossRef] [PubMed]

23. Upchurch, C.P.; Grijalva, C.G.; Wunderink, R.G.; Williams, D.J.; Waterer, G.W.; Anderson, E.J.; Zhu, Y.; Hart, E.M.; Carroll, F.; Bramley, A.M.; et al. Community-acquired Pneumonia Visualized on Computed Tomography but Not Chest X-Ray: Pathogens, Severity, and Clinical Outcomes. *Chest* **2018**, *153*, 601–610. [CrossRef] [PubMed]

24. Bouhemad, B.; Dransart-Rayé, O.; Mojoli, F.; Mongodi, S. Lung ultrasound for diagnosis and monitoring of ventilator-associated pneumonia. *Ann. Transl. Med.* **2018**, *6*, 418. [CrossRef] [PubMed]

25. Parmentier-Decrucq, E.; Poissy, J.; Favory, R.; Nseir, S.; Onimus, T.; Guerry, M.J.; Durocher, A.; Mathieu, D. Adverse events during intrahospital transport of critically ill patients: Incidence and risk factors. *Ann. Intensive Care* **2013**, *3*, 10. [CrossRef]

26. Makris, D.; Desrousseaux, B.; Zakynthinos, E.; Durocher, A.; Nseir, S. The impact of COPD on ICU mortality in patients with ventilator-associated pneumonia. *Respir Med.* **2011**, *105*, 1022–1029. [CrossRef]

27. Nseir, S.; Di Pompeo, C.; Cavestri, B.; Jozefowicz, E.; Nyunga, M.; Soubrier, S.; Roussel-Delvallez, M.; Saulnier, F.; Mathieu, D.; Durocher, A. Multiple-drug-resistant bacteria in patients with severe acute exacerbation of chronic obstructive pulmonary disease: Prevalence, risk factors, and outcome. *Crit. Care Med.* **2006**, *34*, 2959–2966. [CrossRef]

28. Nseir, S.; Di Pompeo, C.; Brisson, H.; Dewavrin, F.; Tissier, S.; Diarra, M.; Boulo, M.; Durocher, A. Intensive care unit-acquired Stenotrophomonas maltophilia: Incidence, risk factors, and outcome. *Crit. Care* **2006**, *10*, R143. [CrossRef]

29. Rodríguez, A.; Lisboa, T.; Solé-Violán, J.; Gómez, F.; Roca, O.; Trefler, S.; Gea, J.; Masclans, J.R.; Rello, J. Impact of nonexacerbated COPD on mortality in critically ill patients. *Chest* **2011**, *139*, 1354–1360. [CrossRef]

<figure><img src="image_5.png" /></figure>